Kodiak Sciences Inc

NASDAQ KOD

Data sourced from iex and EODHD
Download Data

Kodiak Sciences Inc Cash Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 14.16%

Kodiak Sciences Inc Cash Per Share 1 year YoY Change (%) is 14.16% for the Trailing 12 Months (TTM) ending March 31, 2024, a 119.57% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Kodiak Sciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was 4.10, a -72.39% change year over year.
  • Kodiak Sciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was 14.86, a 18.93% change year over year.
  • Kodiak Sciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was 12.49, a 296.32% change year over year.
  • Kodiak Sciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending March 31, 2020 was 3.15, a 163.29% change year over year.
NASDAQ: KOD

Kodiak Sciences Inc

CEO Dr. Victor Perlroth M.D.
IPO Date Oct. 4, 2018
Location United States
Headquarters 1200 Page Mill Road, Palo Alto, CA, United States, 94304
Employees 107
Sector Healthcare
Industry Biotechnology
Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Similar companies

CKPT

Checkpoint Therapeutics Inc

NA

NA

BMEA

Biomea Fusion Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email